舌下含服和皮下注射特异性免疫治疗变应性鼻炎的疗效研究

发布时间：2018-06-14 14:25

本文选题：鼻炎 + 变应性　；参考：《临床耳鼻咽喉头颈外科杂志》2016年09期

【摘要】：目的:研究舌下免疫治疗(SLIT)和皮下免疫治疗(SCIT)变应性鼻炎(AR)的依从性、疗效和安全性。方法:将115例行尘螨脱敏治疗的中-重度持续性AR患者分为SLIT组(64例)和SCIT组(51例)。记录患者的依从情况、治疗前和治疗2年时的症状评分、生活质量评分、药物评分及治疗过程中出现的不良反应。用SPSS 19.0软件对数据进行统计学分析。结果:SLIT组64例患者中40例完成了2年的SLIT,依从率为62.50%;SCIT组51例患者中43例完成了2年的SCIT,依从率为84.31%;2组的依从率差异有统计学意义(P0.05)。接受SLIT和SCIT 2年后,患者的各项症状、生活质量和用药情况较治疗前均有显著改善(均P0.05),但2组之间差异无统计学意义(P0.05)。接受SLIT 2年的40例患者,未出现中重度不良反应;接受SCIT 2年的43例患者,发生了6次中重度不良反应。结论:SLIT与SCIT的疗效相当,SLIT的依从率较低,但安全性明显高于SCIT。
[Abstract]:Objective: to study the compliance, efficacy and safety of sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) in allergic rhinitis. Methods: 115 patients with moderate to severe persistent AR were divided into two groups: slit group (n = 64) and scit group (n = 51). The patient's compliance, symptom score, quality of life score, drug score and adverse reactions before and after treatment were recorded. The data were analyzed by SPSS 19.0 software. Results 40 of 64 patients in the W SLIT group completed SLIT2, and 43 of 51 patients in SCIT group (62.50%) completed SCIT2. The compliance rate was 84.31%. There was significant difference in compliance rate between the two groups (P 0.05). After two years of treatment, the symptoms, quality of life and medication were significantly improved (P 0.05), but there was no significant difference between the two groups (P 0.05). 40 patients who received SLIT for 2 years had no moderate or severe adverse reactions, while 43 patients who received SCIT for 2 years had 6 moderate and severe adverse reactions. Conclusion the compliance rate of the two groups is lower than that of SCIT, but the safety is significantly higher than that of SCITs.
【作者单位】：解放军总医院耳鼻咽喉头颈外科;解放军总医院麻醉手术中心;解放军总医院临床检验科;解放军总医院海南分院耳鼻咽喉头颈外科;
【分类号】：R765.21

【参考文献】